Comparison of the Efficacy of Combined Chemotherapy with Bevacizumab and Apatinib in the Treatment of Recurrent Glioma
Objective To compare the efficacy of combined chemotherapy with bevacizumab and apatinib in the treatment of recurrent glioma.Methods From January 2021 to October 2022,a total of 92 patients with recurrent glioma treated at the Nantong Tumor Hospital were selected as the study subjects.Patients were divided into the bevacizumab group and the apatinib group using the random number table method,with 46 patients in each group.Patients in the bevacizumab group were given temozolomide capsules orally and bevacizumab injection intravenously,patients in the apatinib group were given temozolomide capsules and apatinib mesylate tablets orally,4 weeks was 1 treatment cycle,and both groups were treated for 3 treatment cycles.The clinical efficacy,serological indexes[vascular endothelial growth factor(VEGF),epidermal growth factor receptor(EGFR),glial fibrillary acidic protein(GFAP),and chitinase protein-40(YKL-40)]and Karnofsky score before and after treatment,survival rate,and the occurrence of toxicities during the treatment were compared between the two groups.Results The objective response rate of apatinib group was higher than that of bevacizumab group(P＜0.05).There was no significant difference in disease control rate between the two groups(P＞0.05).After treatment,VEGF,EGFR,GFAP,and YKL-40 of apatinib group were lower than those of bevacizumab group(P＜0.05).The Karnofsky score of apatinib group was higher than that of bevacizumab group(P＜0.05).Cumulative survival rate of apatinib group was higher than that of bevacizumab group(P＜0.05).The incidence of hypertension and proteinuria in the apatinib group was lower than that in the bevacizumab group(P＜0.05).Conclusion Compared with bevacizumab combination chemotherapy,apatinib combination chemotherapy can increase the objective remission rates of patients with recurrent gliomas,reduce cytokines,increase the quality of life and survival rate,and reduce the incidence of toxicities.
万方数据
维普
